Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 71.98 Billion KRW | 18.95% |
| 2022 | 60.46 Billion KRW | 20.37% |
| 2021 | 50.23 Billion KRW | 12.34% |
| 2020 | 44.71 Billion KRW | -2.13% |
| 2019 | 45.69 Billion KRW | 4.91% |
| 2018 | 43.55 Billion KRW | 11.28% |
| 2017 | 39.13 Billion KRW | 2.41% |
| 2016 | 38.21 Billion KRW | -7.2% |
| 2015 | 41.18 Billion KRW | 4.97% |
| 2014 | 39.22 Billion KRW | -12.3% |
| 2013 | 44.73 Billion KRW | 16.14% |
| 2012 | 38.51 Billion KRW | -24.67% |
| 2011 | 51.12 Billion KRW | 3.68% |
| 2010 | 49.31 Billion KRW | 6.57% |
| 2009 | 46.26 Billion KRW | -8.35% |
| 2008 | 50.48 Billion KRW | 3.02% |
| 2007 | 49 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 33.97 Billion KRW | 81.84% |
| 2024 Q2 | 34.65 Billion KRW | 1.99% |
| 2024 Q3 | 36.41 Billion KRW | -44.11% |
| 2023 Q3 | -17.45 Billion KRW | 8.52% |
| 2023 Q4 | 18.68 Billion KRW | 207.03% |
| 2023 Q2 | -19.08 Billion KRW | -209.27% |
| 2023 Q1 | 17.46 Billion KRW | 3.14% |
| 2023 FY | 71.92 Billion KRW | 18.95% |
| 2022 Q1 | 13.37 Billion KRW | 2.39% |
| 2022 Q3 | 15.89 Billion KRW | 11.5% |
| 2022 Q4 | 16.93 Billion KRW | 6.49% |
| 2022 FY | 60.46 Billion KRW | 20.37% |
| 2022 Q2 | 14.25 Billion KRW | 6.61% |
| 2021 Q1 | 12.39 Billion KRW | 4.75% |
| 2021 Q3 | 12.63 Billion KRW | 4.1% |
| 2021 Q4 | 13.06 Billion KRW | 3.41% |
| 2021 Q2 | 12.13 Billion KRW | -2.13% |
| 2021 FY | 50.23 Billion KRW | 12.34% |
| 2020 FY | 44.71 Billion KRW | -2.13% |
| 2020 Q2 | 11.16 Billion KRW | 5.4% |
| 2020 Q3 | 11.11 Billion KRW | -0.49% |
| 2020 Q1 | 10.59 Billion KRW | 3.84% |
| 2020 Q4 | 11.83 Billion KRW | 6.51% |
| 2019 FY | 45.69 Billion KRW | 4.91% |
| 2019 Q2 | 11.86 Billion KRW | 2.65% |
| 2019 Q3 | 12.07 Billion KRW | 1.78% |
| 2019 Q4 | 10.2 Billion KRW | -15.47% |
| 2019 Q1 | 11.55 Billion KRW | 4.68% |
| 2018 Q2 | 10.46 Billion KRW | -11.34% |
| 2018 FY | 43.55 Billion KRW | 11.28% |
| 2018 Q4 | 11.03 Billion KRW | 7.76% |
| 2018 Q3 | 10.24 Billion KRW | -2.14% |
| 2018 Q1 | 11.8 Billion KRW | 43.71% |
| 2017 Q1 | 9.88 Billion KRW | 4.9% |
| 2017 Q4 | 8.21 Billion KRW | -26.64% |
| 2017 FY | 39.13 Billion KRW | 2.41% |
| 2017 Q2 | 9.83 Billion KRW | -0.5% |
| 2017 Q3 | 11.19 Billion KRW | 13.82% |
| 2016 Q4 | 9.42 Billion KRW | -7.02% |
| 2016 FY | 38.21 Billion KRW | -7.2% |
| 2016 Q1 | 9.24 Billion KRW | -18.86% |
| 2016 Q2 | 9.41 Billion KRW | 1.83% |
| 2016 Q3 | 10.13 Billion KRW | 7.72% |
| 2015 Q4 | 11.38 Billion KRW | 7.88% |
| 2015 Q2 | 9.42 Billion KRW | -3.83% |
| 2015 Q3 | 10.55 Billion KRW | 11.96% |
| 2015 Q1 | 9.8 Billion KRW | -7.21% |
| 2015 FY | 41.18 Billion KRW | 4.97% |
| 2014 Q3 | 9.67 Billion KRW | 0.39% |
| 2014 FY | 39.22 Billion KRW | -12.3% |
| 2014 Q1 | 9.35 Billion KRW | -25.39% |
| 2014 Q4 | 10.56 Billion KRW | 9.24% |
| 2014 Q2 | 9.63 Billion KRW | 2.98% |
| 2013 FY | 44.73 Billion KRW | 16.14% |
| 2013 Q4 | 12.53 Billion KRW | 4.41% |
| 2013 Q3 | 12 Billion KRW | 13.98% |
| 2013 Q2 | 10.53 Billion KRW | 9.2% |
| 2013 Q1 | 9.64 Billion KRW | -6.34% |
| 2012 Q2 | 9.37 Billion KRW | 2.7% |
| 2012 FY | 38.51 Billion KRW | -24.67% |
| 2012 Q4 | 10.3 Billion KRW | 13.76% |
| 2012 Q3 | 9.05 Billion KRW | -3.36% |
| 2012 Q1 | 9.12 Billion KRW | 0.0% |
| 2011 Q2 | 15.29 Billion KRW | 34.09% |
| 2011 FY | 51.12 Billion KRW | 3.68% |
| 2011 Q1 | 11.4 Billion KRW | -0.17% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 12.39 Billion KRW | -18.95% |
| 2010 Q1 | 11.82 Billion KRW | -1.56% |
| 2010 FY | 49.31 Billion KRW | 6.57% |
| 2010 Q4 | 11.42 Billion KRW | -11.25% |
| 2010 Q3 | 12.87 Billion KRW | -2.42% |
| 2010 Q2 | 13.19 Billion KRW | 11.55% |
| 2009 Q2 | 12.4 Billion KRW | 11.86% |
| 2009 Q1 | 11.09 Billion KRW | -20.12% |
| 2009 Q3 | 10.75 Billion KRW | -13.3% |
| 2009 Q4 | 12.01 Billion KRW | 11.66% |
| 2009 FY | 46.26 Billion KRW | -8.35% |
| 2008 Q3 | 12.92 Billion KRW | 6.54% |
| 2008 Q4 | 13.88 Billion KRW | 7.47% |
| 2008 FY | 50.48 Billion KRW | 3.02% |
| 2008 Q1 | 11.54 Billion KRW | -10.19% |
| 2008 Q2 | 12.12 Billion KRW | 5.0% |
| 2007 FY | 49 Billion KRW | 0.0% |
| 2007 Q2 | 11.85 Billion KRW | -3.84% |
| 2007 Q3 | 11.95 Billion KRW | 0.8% |
| 2007 Q1 | 12.33 Billion KRW | 0.0% |
| 2007 Q4 | 12.85 Billion KRW | 7.58% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -52.333% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 75.844% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 74.148% |
| HANDOK Inc. | 153.76 Billion KRW | 53.187% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -4.002% |
| Yuhan Corporation | 489.94 Billion KRW | 85.308% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 76.549% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -72.252% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 88.218% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 58.666% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -79.72% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 23.055% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 37.256% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -52.333% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -69.485% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 4.085% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -22.746% |
| JW Holdings Corporation | 301.25 Billion KRW | 76.106% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 72.416% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 82.385% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 69.87% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 43.617% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -5.376% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -9.478% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 58.849% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -52.333% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 71.105% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 87.156% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 69.87% |
| Yuhan Corporation | 489.94 Billion KRW | 85.308% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 62.831% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -3.62% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -28.468% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 69.87% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 43.048% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 39.108% |
| CKD Bio Corp. | 25.19 Billion KRW | -185.696% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 67.575% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 56.404% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -8.38% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 43.617% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 79.475% |
| Boryung Corporation | 285.16 Billion KRW | 74.757% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 17.773% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 58.666% |
| JW Lifescience Corporation | 20.26 Billion KRW | -255.27% |